Stroke patients treated by thrombectomy in real life differ from cohorts of the clinical trials: a prospective observational study.


Journal

BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555

Informations de publication

Date de publication:
05 Mar 2020
Historique:
received: 24 02 2019
accepted: 24 02 2020
entrez: 7 3 2020
pubmed: 7 3 2020
medline: 31 7 2020
Statut: epublish

Résumé

Randomized controlled trials (RCTs) demonstrated efficacy and safety of endovascular treatment (ET) in anterior circulation large vessel occlusions (LVO). We aimed at investigating how stroke patients treated by thrombectomy in clinical practice and their outcome compare to cohorts and results of thrombectomy trials. In a prospective study, we consecutively included stroke patients treated by thrombectomy (2015-2017). Baseline characteristics, procedural and outcome data were analyzed. Outcome was assessed by modified Rankin Scale (mRS) at 90 days. Ordinal regression analysis was performed to identify predictors of outcome. Thrombectomy was applied in 264 patients (median 75 years, 49.6% female). Median baseline National Institutes of Health Stroke Scale (NIHSS) was 16, 58.0% received concomitant intravenous thrombolysis, 62.1% were referred from external hospitals. Median Alberta Stroke Program Early CT Score (ASPECTS) was 7. Successful recanalization (modified Thrombolysis in Cerebral Infarction Score, mTICI 2b/3) was achieved in 72.0%. Symptomatic intracranial hemorrhage (sICH) occurred in 4.5%. Independent outcome (mRS 0-2) was achieved in 26.2%, poor outcome (mRS 5-6) in 49.2%. Only 33.5% met the stringent enrolment criteria of previous RCTs. Lower age, baseline NIHSS, pre-stroke mRS, higher ASPECTS, and successful recanalization were independent predictors of favourable outcome. The majority of stroke patients treated by ET in clinical practice would not have qualified for randomization in prior RCTs. Outcome in real-life patient cohorts is worse than in the highly selected cohorts from randomized trials, while rates of successful recanalization, sICH and outcome predictors are the same. Our findings support ET in broader patient populations than in the RCTs and may improve treatment decision in individual stroke patients with LVO in clinical practice.

Sections du résumé

BACKGROUND BACKGROUND
Randomized controlled trials (RCTs) demonstrated efficacy and safety of endovascular treatment (ET) in anterior circulation large vessel occlusions (LVO). We aimed at investigating how stroke patients treated by thrombectomy in clinical practice and their outcome compare to cohorts and results of thrombectomy trials.
METHODS METHODS
In a prospective study, we consecutively included stroke patients treated by thrombectomy (2015-2017). Baseline characteristics, procedural and outcome data were analyzed. Outcome was assessed by modified Rankin Scale (mRS) at 90 days. Ordinal regression analysis was performed to identify predictors of outcome.
RESULTS RESULTS
Thrombectomy was applied in 264 patients (median 75 years, 49.6% female). Median baseline National Institutes of Health Stroke Scale (NIHSS) was 16, 58.0% received concomitant intravenous thrombolysis, 62.1% were referred from external hospitals. Median Alberta Stroke Program Early CT Score (ASPECTS) was 7. Successful recanalization (modified Thrombolysis in Cerebral Infarction Score, mTICI 2b/3) was achieved in 72.0%. Symptomatic intracranial hemorrhage (sICH) occurred in 4.5%. Independent outcome (mRS 0-2) was achieved in 26.2%, poor outcome (mRS 5-6) in 49.2%. Only 33.5% met the stringent enrolment criteria of previous RCTs. Lower age, baseline NIHSS, pre-stroke mRS, higher ASPECTS, and successful recanalization were independent predictors of favourable outcome.
CONCLUSIONS CONCLUSIONS
The majority of stroke patients treated by ET in clinical practice would not have qualified for randomization in prior RCTs. Outcome in real-life patient cohorts is worse than in the highly selected cohorts from randomized trials, while rates of successful recanalization, sICH and outcome predictors are the same. Our findings support ET in broader patient populations than in the RCTs and may improve treatment decision in individual stroke patients with LVO in clinical practice.

Identifiants

pubmed: 32138684
doi: 10.1186/s12883-020-01653-z
pii: 10.1186/s12883-020-01653-z
pmc: PMC7059360
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

81

Références

J Neuroradiol. 2018 Jul;45(4):211-216
pubmed: 29470997
N Engl J Med. 2015 Jun 11;372(24):2285-95
pubmed: 25882376
N Engl J Med. 2018 Feb 22;378(8):708-718
pubmed: 29364767
Lancet. 2007 Jan 27;369(9558):275-82
pubmed: 17258667
N Engl J Med. 2015 Jan 1;372(1):11-20
pubmed: 25517348
Neurol Neurochir Pol. 2017 Jan - Feb;51(1):12-18
pubmed: 27717502
J Neurointerv Surg. 2016 Nov;8(11):1107-1115
pubmed: 26610730
Lancet. 2016 Apr 23;387(10029):1723-31
pubmed: 26898852
World Neurosurg. 2017 Aug;104:1-8
pubmed: 28427984
N Engl J Med. 2015 Mar 12;372(11):1019-30
pubmed: 25671798
J Stroke Cerebrovasc Dis. 2017 Dec;26(12):2793-2799
pubmed: 28754235
ScientificWorldJournal. 2015;2015:403726
pubmed: 26137591
N Engl J Med. 2015 Mar 12;372(11):1009-18
pubmed: 25671797
J Korean Neurosurg Soc. 2017 Nov;60(6):635-643
pubmed: 29142622
Clin Neuroradiol. 2018 Sep;28(3):313-326
pubmed: 29744519
Neuroradiology. 2018 Feb;60(2):123-126
pubmed: 29275515
N Engl J Med. 2018 Jan 4;378(1):11-21
pubmed: 29129157
Stroke. 2015 Oct;46(10):3020-35
pubmed: 26123479
J Neurointerv Surg. 2018 Jun;10(6):516-524
pubmed: 28963367
N Engl J Med. 2015 Jun 11;372(24):2296-306
pubmed: 25882510

Auteurs

Milani Deb-Chatterji (M)

Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. m.deb-chatterji@uke.de.

Hans Pinnschmidt (H)

Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Fabian Flottmann (F)

Department of Neuroradiological Diagnostics and Intervention, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Hannes Leischner (H)

Department of Neuroradiological Diagnostics and Intervention, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Anna Alegiani (A)

Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.

Caspar Brekenfeld (C)

Department of Neuroradiological Diagnostics and Intervention, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Jens Fiehler (J)

Department of Neuroradiological Diagnostics and Intervention, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Christian Gerloff (C)

Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.

Götz Thomalla (G)

Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH